Bispecific antibodies or so-called BiTEs are able to connect T cells and B cells as target cells by simultaneously binding two proteins. The T cell is thus activated and leads to a precise depletion of the target cells. In this Expert Opinion, Prof. Dr. Dr. Dr. Sven G. Meuth explains why BiTEs represent a promising therapeutic approach for patients with myasthenia gravis and what clinical evidence is already available.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this Expert Opinion you will know:
- the mechanism of action of BiTEs
- the advantages of BiTEs compared to other therapy options
- Current study results on the therapeutic potential for myasthenia gravis
